Kalpress Plus

Valsartan, the active ingredient in Kalpress Plus, is an angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension, often combined with hydrochlorothiazide, and is prescribed for adult patients. GNH USA supplies Kalpress Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kalpress Plus combines an ARB with a thiazide diuretic to manage elevated blood pressure. It is used in the following conditions: - Hypertension: lowers systolic and diastolic pressure and reduces cardiovascular risk. - Essential hypertension: provides consistent blood‑pressure control when monotherapy is insufficient. - Hypertension requiring diuretic therapy: adds diuretic effect to improve fluid balance and further reduce pressure.

Kalpress Plus may cause a range of adverse reactions. The most frequently reported are generally mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Low potassium levels (hypokalemia) - Elevated blood glucose

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, angioedema) - Acute kidney injury or worsening renal function - Marked hypotension (very low blood pressure) - Hyperkalemia (high potassium) - Pancreatitis - Blood dyscrasias such as agranulocytosis

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor key parameters. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function: assess creatinine and eGFR periodically. - Electrolytes: check potassium and sodium levels, especially with diuretic use. - Elderly patients: start at lower doses and monitor for orthostatic symptoms. - Pregnancy: safety not established; avoid use during pregnancy. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Kalpress Plus can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - ACE inhibitors or aliskiren: risk of severe hyperkalemia and renal failure. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - Lithium: increased lithium levels and toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function. - Antidiabetic agents: enhanced hypoglycemic effect, monitor glucose levels.